CUE
Cue Biopharma
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
CUE fundamentals
Cue Biopharma (CUE) expects to report earnings on Aug 13, 2025, with estimated revenue of 2.00M (YoY -24.81%), and EPS at -0.13 (YoY +35.00%).
Revenue estimate / YoY
2.00M
-24.81%
EPS estimate / YoY
-0.13
+35.00%
Report date
Aug 13, 2025
EPS
Revenue
Revenue & Expenses
CUE has released its 2025 Q1 earnings report, with revenue of 421.00K, reflecting a YoY change of -75.48%, and net profit of -12.26M, showing a YoY change of 0.73%. The Sankey diagram below clearly presents CUE's revenue sources and cost distribution.
Key Indicators
Cue Biopharma (CUE) key financial stats and ratios, covering profitability, financial health, and leverage.
Cue Biopharma (CUE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Cue Biopharma (CUE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Cue Biopharma (CUE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Cue Biopharma (CUE) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Cue Biopharma (CUE) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What does Cue Biopharma do and what are its main business segments?What guidance did Cue Biopharma’s management provide for the next earnings period? What is Cue Biopharma’s latest dividend and current dividend yield?Did Cue Biopharma beat or miss consensus estimates last quarter?What were the key takeaways from Cue Biopharma’s earnings call?What is the market’s earnings forecast for Cue Biopharma next quarter?What factors drove the changes in Cue Biopharma’s revenue and profit?How were Cue Biopharma’s latest financial results overall?